B. 1. Taylor, G. W. Meltzer, and A. , "Inflammatory Carcinoma" of the Breast, The American Journal of Cancer, vol.33, issue.1, pp.33-49, 1938.
DOI : 10.1158/ajc.1938.33

B. Lee and N. Tannenbaum, Inflammatory carcinoma of the breast: a report of twenty-­? eight cases from the breast clinic of Memorial Hospital, Surg Gynecol Obstet, vol.39, p.580, 1924.

W. F. Anderson, C. Schairer, B. E. Chen, K. W. Hance, and P. Levine, Epidemiology of Inflammatory Breast Cancer (IBC)1, Breast Disease, vol.22, issue.1, pp.9-23, 2005.
DOI : 10.3233/BD-2006-22103

A. Gogia, Inflammatory breast cancer: a single centre analysis. Asian Pac, J

A. M. Gonzalez-­?angulo, Trends for Inflammatory Breast Cancer: Is Survival Improving?, The Oncologist, vol.12, issue.8, pp.904-912, 2007.
DOI : 10.1634/theoncologist.12-8-904

N. M. Rueth, Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database, Journal of Clinical Oncology, vol.32, issue.19, pp.2018-2024, 2014.
DOI : 10.1200/JCO.2014.55.1978

P. A. Wingo, P. M. Jamison, J. L. Young, and P. Gargiullo, Population-Based Statistics for Women Diagnosed with Inflammatory Breast Cancer (United States), Cancer Causes & Control, vol.15, issue.3, pp.321-328, 2004.
DOI : 10.1023/B:CACO.0000024222.61114.18

P. Bonnier, Influence of pregnancy on the outcome of breast cancer: a case-­? control study

L. Amiri-­?kordestani, F. Kamangar, and J. A. Zujewski, Inflammatory Breast Cancer: Yet Another Risk of the Obesity Epidemic?, JNCI Journal of the National Cancer Institute, vol.105, issue.18, pp.1340-1342, 2013.
DOI : 10.1093/jnci/djt236

W. A. Woodward and M. Cristofanilli, Inflammatory Breast Cancer, Seminars in Radiation Oncology, vol.19, issue.4, pp.256-265, 2009.
DOI : 10.1016/j.semradonc.2009.05.008

C. Schairer, Risk Factors for Inflammatory Breast Cancer and Other Invasive Breast Cancers, JNCI Journal of the National Cancer Institute, vol.105, issue.18, pp.1373-1384, 2013.
DOI : 10.1093/jnci/djt206

S. Hashmi, L. Zolfaghari, and P. H. Levine, Does Secondary Inflammatory Breast Cancer Represent Post-Surgical Metastatic Disease?, Cancers, vol.4, issue.4, pp.156-164, 2012.
DOI : 10.3390/cancers4010156

S. E. Singletary and M. Cristofanilli, Defining the Clinical Diagnosis of Inflammatory Breast Cancer, Seminars in Oncology, vol.35, issue.1, pp.7-10, 2008.
DOI : 10.1053/j.seminoncol.2007.11.010

K. W. Hance, W. F. Anderson, S. S. Devesa, H. A. Young, and P. H. Levine, Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute, JNCI Journal of the National Cancer Institute, vol.97, issue.13, pp.966-975, 2005.
DOI : 10.1093/jnci/dji172

M. Boisserie-­?lacroix, The inflammatory breast: Management, decision-making algorithms, therapeutic principles, Diagnostic and Interventional Imaging, vol.93, issue.2, pp.126-136, 2012.
DOI : 10.1016/j.diii.2011.12.005

P. Bonnier, Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition?, International Journal of Cancer, vol.33, issue.4, pp.382-385, 1995.
DOI : 10.1002/ijc.2910620404

H. Yamauchi, Inflammatory Breast Cancer: What We Know and What We Need to Learn, The Oncologist, vol.17, issue.7, pp.891-899, 2012.
DOI : 10.1634/theoncologist.2012-0039

S. J. Van-laere, Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets, Clinical Cancer Research, vol.19, issue.17, pp.4685-4696, 2013.
DOI : 10.1158/1078-0432.CCR-12-2549

A. Prat, Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Research, vol.15, issue.1, p.68, 2010.
DOI : 10.1038/nm0809-842

D. M. Nguyen, Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype, Clinical Cancer Research, vol.12, issue.17, pp.5047-5054, 2006.
DOI : 10.1158/1078-0432.CCR-05-2248

Y. Ye, E-­?cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking, Anticancer Res, vol.30, pp.3903-3910, 2010.

E. Charafe-­?jauffret, Immunophenotypic analysis of inflammatory breast cancers: identification of an???inflammatory signature???, The Journal of Pathology, vol.202, issue.3, pp.265-273, 2004.
DOI : 10.1002/path.1515

A. Paradiso, M. , and S. T. , Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease, Cancer, vol.68, issue.9, pp.1922-1927, 2006.
DOI : 10.1002/1097-0142(19891101)64:9<1922::AID-CNCR2820640927>3.0.CO;2-I

M. Guérin, Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance, International Journal of Cancer, vol.49, issue.2, pp.201-208, 1989.
DOI : 10.1002/ijc.2910430205

T. M. Fouad, T. Kogawa, J. M. Reuben, and N. Ueno, The Role of Inflammation in Inflammatory Breast Cancer, Adv. Exp. Med. Biol, vol.816, pp.53-73, 2014.
DOI : 10.1007/978-3-0348-0837-8_3

S. B. Fox, D. G. Generali, and A. L. Harris, Breast tumour angiogenesis, Breast Cancer Research, vol.11, issue.Suppl 5, p.216, 2007.
DOI : 10.1186/bcr1796

N. J. Mccarthy, Microvessel density, expression of estrogen receptor alpha, MIB-­?1, p53, and c-­?erbB-­?2 in inflammatory breast cancer, Clin. Cancer Res. Off. J. Am

C. G. Colpaert, Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression, British Journal of Cancer, vol.88, issue.5, pp.718-725, 2003.
DOI : 10.1038/sj.bjc.6600807

E. Turpin, Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer, Oncogene, vol.21, issue.49, pp.7593-7597, 2002.
DOI : 10.1038/sj.onc.1205932

A. M. Gonzalez-­?angulo, p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer, Clinical Cancer Research, vol.10, issue.18, pp.6215-6221, 2004.
DOI : 10.1158/1078-0432.CCR-04-0202

C. G. Kleer, K. L. Van-golen, and S. Merajver, Molecular biology of breast cancer metastasis Inflammatory breast cancer: clinical syndrome and molecular determinants, Breast Cancer Research, vol.1, issue.6, pp.423-429, 2000.
DOI : 10.1007/BF02096306

K. L. Van-golen, A novel putative low-­?affinity insulin-­?like growth factor-­? binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.5, pp.2511-2519, 1999.

K. L. Van-golen, Z. Wu, X. Qiao, L. Bao, and S. D. Merajver, RhoC GTPase Overexpression Modulates Induction of Angiogenic Factors in Breast Cells, Neoplasia, vol.2, issue.5
DOI : 10.1038/sj.neo.7900115

C. G. Kleer, RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast, Breast Cancer Research and Treatment, vol.2, issue.Pt2, pp.101-110, 2005.
DOI : 10.1007/s10549-005-4170-6

S. J. Van-laere, Nuclear Factor-??B Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-??B DNA-Binding, Clinical Cancer Research, vol.12, issue.11, pp.3249-3256, 2006.
DOI : 10.1158/1078-0432.CCR-05-2800

M. El-­?shinawi, Human Cytomegalovirus Infection Enhances NF-??B/p65 Signaling in Inflammatory Breast Cancer Patients, PLoS ONE, vol.1, issue.2, p.55755, 2013.
DOI : 10.1371/journal.pone.0055755.s001

F. M. Robertson, Presence of anaplastic lymphoma kinase in inflammatory breast cancer, SpringerPlus, vol.2, issue.1, 2013.
DOI : 10.1021/pr7008127

K. Y. Ha, S. B. Glass, and L. Laurie, Inflammatory breast carcinoma, Proc. Bayl. Univ

U. Mammographic, Clinical, and Pathologic Findings in 142 Cases, Radiology, vol.223, pp.829-838, 2002.

A. C. Kushwaha, G. J. Whitman, C. B. Stelling, M. Cristofanilli, and A. Buzdar, Primary Inflammatory Carcinoma of the Breast, American Journal of Roentgenology, vol.174, issue.2, pp.535-538, 2000.
DOI : 10.2214/ajr.174.2.1740535

W. T. Yang, Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings, Breast Cancer Research and Treatment, vol.7, issue.3, pp.417-426, 2008.
DOI : 10.1007/s10549-007-9671-z

S. Sager, S. Asa, R. K. Doner, C. Leblebici, and M. Halac, Initial evaluation of inflammatory breast cancer with fluorodeoxyglucose positron emission tomography, Indian Journal of Nuclear Medicine, vol.27, issue.1
DOI : 10.4103/0972-3919.108843

S. Carkaci, Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data, Journal of Nuclear Medicine, vol.50, issue.2, pp.231-238, 2009.
DOI : 10.2967/jnumed.108.056010

S. Dawood, International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment, Annals of Oncology, vol.22, issue.3
DOI : 10.1093/annonc/mdq345

H. Masuda, Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes, Annals of Oncology, vol.25, issue.2
DOI : 10.1093/annonc/mdt525

J. M. Matro, Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome, Clinical Breast Cancer, vol.15, issue.1, pp.1-7, 2015.
DOI : 10.1016/j.clbc.2014.05.005

K. C. Horst, M. C. Smitt, D. R. Goffinet, and R. W. Carlson, Predictors of Local Recurrence After Breast-Conservation Therapy, Clinical Breast Cancer, vol.5, issue.6, pp.425-438, 2005.
DOI : 10.3816/CBC.2005.n.001

L. D. Curcio, Beyond Palliative Mastectomy in Inflammatory Breast Cancer?A Reassessment of Margin Status, Annals of Surgical Oncology, vol.18, issue.3, pp.249-254, 1999.
DOI : 10.1007/s10434-999-0249-3

I. J. Bristol, Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.72, issue.2, pp.474-484, 2008.
DOI : 10.1016/j.ijrobp.2008.01.039

T. Palangie, Prognostic factors in inflammatory breast cancer and therapeutic implications, European Journal of Cancer, vol.30, issue.7, pp.921-927, 1990.
DOI : 10.1016/0959-8049(94)90115-5

D. Makower and J. A. Sparano, How Do I Treat Inflammatory Breast Cancer?, Current Treatment Options in Oncology, vol.116, issue.11 Suppl, pp.66-74, 2013.
DOI : 10.1007/s11864-012-0214-4

J. Rouëssé, Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy., Journal of Clinical Oncology, vol.4, issue.12, pp.1765-1771, 1986.
DOI : 10.1200/JCO.1986.4.12.1765

G. Robbins, Inflammatory Carcinoma of the Breast, Surgical Clinics of North America, vol.54, issue.4, pp.801-810, 1974.
DOI : 10.1016/S0039-6109(16)40383-X

M. Cristofanilli, Inflammatory breast cancer (IBC) and patterns of recurrence, Cancer, vol.10, issue.7, pp.1436-1444, 2007.
DOI : 10.1002/cncr.22927

. Blumenschein, Sequential combined modality therapy for inflammatory breast cancer, Breast, vol.1620, 1976.

N. T. Ueno, Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center, Cancer Chemotherapy and Pharmacology, vol.40, issue.4, pp.321-329, 1997.
DOI : 10.1007/s002800050664

M. Cristofanilli, Paclitaxel in the multimodality treatment for inflammatory breast carcinoma, Cancer, vol.4, issue.7, pp.1775-1782, 2001.
DOI : 10.1002/1097-0142(20011001)92:7<1775::AID-CNCR1693>3.0.CO;2-E

M. Cristofanilli, Paclitaxel Improves the Prognosis in Estrogen Receptor???Negative Inflammatory Breast Cancer: The M. D. Anderson Cancer Center Experience, Clinical Breast Cancer, vol.4, issue.6, pp.415-419, 2004.
DOI : 10.3816/CBC.2004.n.004

M. Kaufmann, Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update, Journal of Clinical Oncology, vol.24, issue.12
DOI : 10.1200/JCO.2005.02.6187

A. B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler, Reporting results of cancer treatment, Cancer, vol.11, issue.1, pp.207-214, 1981.
DOI : 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

P. Therasse, New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000.
DOI : 10.1093/jnci/92.3.205

N. Sneige, B. Kemp, L. Pusztai, L. Asmar, and G. N. Hortobagyi, Chemotherapy-induced histologic changes in mastectomy specimens and their potential significance, The Breast, vol.10, issue.6, pp.492-500, 2001.
DOI : 10.1054/brst.2001.0310

B. Chevallier, H. Roche, J. P. Olivier, P. Chollet, and P. Hurteloup, Inflammatory Breast Cancer, American Journal of Clinical Oncology, vol.16, issue.3, pp.223-228, 1993.
DOI : 10.1097/00000421-199306000-00006

D. M. Sataloff, Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome, J. Am. Coll. Surg, vol.180, pp.297-79, 1995.

R. Y. Fleming, Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma, Annals of Surgical Oncology, vol.83, issue.6, pp.452-461, 1997.
DOI : 10.1007/BF02303668

S. Abrous-­?anane, Traitement locor??gional du cancer du sein inflammatoire apr??s chimioth??rapie n??oadjuvante, Cancer/Radioth??rapie, vol.15, issue.8, pp.654-662, 2011.
DOI : 10.1016/j.canrad.2011.01.009

T. Bates, N. J. Williams, S. Bendall, E. E. Bassett, and R. S. Coltart, Primary chemo-radiotherapy in the treatment of locally advanced and inflammatory breast cancer, The Breast, vol.21, issue.3
DOI : 10.1016/j.breast.2012.02.002

D. Boer and R. H. , Multimodality therapy in inflammatory breast cancer: is there a place for surgery?, Annals of Oncology, vol.11, issue.9, pp.1147-1153, 2000.
DOI : 10.1023/A:1008374931854

S. Hidar, Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer, International Journal of Surgery, vol.7, issue.3, pp.272-275, 2009.
DOI : 10.1016/j.ijsu.2009.04.012

V. Bonev, Long-­?term Follow-­?up of Breast-­?conserving Therapy in Patients with Inflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy, Am. Surg, vol.80, pp.940-943, 2014.

P. L. Chin, Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile?11No competing interests declared., Journal of the American College of Surgeons, vol.190, issue.3, pp.304-309, 2000.
DOI : 10.1016/S1072-7515(99)00267-7

E. I. Chang, Challenging a Traditional Paradigm, Plastic and Reconstructive Surgery, vol.135, issue.2, pp.262-271, 2015.
DOI : 10.1097/PRS.0000000000000900

N. Aomatsu, Usefulness of immediate reconstruction after mastectomy for inflammatory breast cancer with muscle cutaneous flap], Gan To Kagaku Ryoho, vol.38, pp.2165-2167, 2011.

W. A. Woodward and T. A. Buchholz, The Role of Locoregional Therapy in Inflammatory Breast Cancer, Seminars in Oncology, vol.35, issue.1, pp.78-86, 2008.
DOI : 10.1053/j.seminoncol.2007.11.009

W. A. Woodward, B. G. Debeb, W. Xu, and T. A. Buchholz, Overcoming radiation resistance in inflammatory breast cancer, Cancer, vol.66, issue.1 suppl, pp.2840-2845, 2010.
DOI : 10.1002/cncr.25173

Z. Liao, Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence, International Journal of Radiation Oncology*Biology*Physics, vol.47, issue.5, pp.1191-1200, 2000.
DOI : 10.1016/S0360-3016(00)00561-7

C. Veyret, Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy, Cancer, vol.1, issue.11, pp.2535-2544, 2006.
DOI : 10.1002/cncr.22227

C. Early-breast and . Trialists, Collaborative Group (EBCTCG) et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-­?level meta-­?analysis of randomised trials, Lancet, vol.378, pp.771-784, 2011.

M. Dowsett, Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen, Journal of Clinical Oncology, vol.28, issue.3, pp.509-518, 2010.
DOI : 10.1200/JCO.2009.23.1274

P. A. Francis, Adjuvant Ovarian Suppression in Premenopausal Breast Cancer, New England Journal of Medicine, vol.372, issue.5, pp.436-446, 2015.
DOI : 10.1056/NEJMoa1412379

O. Pagani, Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer, New England Journal of Medicine, vol.371, issue.2, pp.107-118, 2014.
DOI : 10.1056/NEJMoa1404037

C. Davies, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, The Lancet, vol.381, issue.9869, pp.805-816, 2013.
DOI : 10.1016/S0140-6736(12)61963-1

R. C. Jankowitz and N. Davidson, Adjuvant endocrine therapy for breast cancer: how long is long enough? Oncol, Williston Park N, vol.27, pp.1210-1216, 2013.

A. Monneur, F. Bertucci, P. Viens, and A. Gonçalves, Systemic treatments of inflammatory breast cancer: an overview, Bull. Cancer (Paris), vol.101, pp.1080-1088, 2014.

L. Gianni, Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort, The Lancet Oncology, vol.15, issue.6, pp.640-647, 2014.
DOI : 10.1016/S1470-2045(14)70080-4

J. Pierga, Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data, Clinical Cancer Research, vol.21, issue.6, 2014.
DOI : 10.1158/1078-0432.CCR-14-1705

B. Kaufman, Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study, The Lancet Oncology, vol.10, issue.6, pp.581-588, 2009.
DOI : 10.1016/S1470-2045(09)70087-7

M. Mego, Circulating tumor cells in newly diagnosed inflammatory breast 81 cancer, Breast Cancer Res. BCR, vol.17, 2015.

T. M. Brewer, Statin use in primary inflammatory breast cancer: a cohort study, British Journal of Cancer, vol.42, issue.2, pp.318-324, 2013.
DOI : 10.1093/carcin/bgh201

A. Clifford and W. E. Hudis, Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.25, pp.2127-2159, 2007.

M. Moossdorff, Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research, JNCI Journal of the National Cancer Institute, vol.106, issue.12, 2014.
DOI : 10.1093/jnci/dju288

H. J. Shin, Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy, The British Journal of Radiology, vol.84, issue.1003, pp.612-620, 2011.
DOI : 10.1259/bjr/74430952

H. J. Hoffman, Initial Response to Chemotherapy, Not Delay in Diagnosis, Predicts Overall Survival in Inflammatory Breast Cancer Cases, American Journal of Clinical Oncology, vol.37, issue.4, pp.315-321, 2014.
DOI : 10.1097/COC.0b013e318271b34b

E. Lambaudie, Traitement chirurgical conservateur de la récidive locale d'un cancer du sein, 2009.

G. Van-tienhoven, Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM), European Journal of Cancer, vol.35, issue.1, pp.32-38, 1990.
DOI : 10.1016/S0959-8049(98)00301-3

R. Chairat, Recurrence and death from breast cancer after complete treatments: an experience from hospitals in Northern Thailand, J. Med. Assoc. Thail. Chotmaihet Thangphaet, vol.97, pp.932-938, 2014.

J. S. Wecsler, Lymph node status in inflammatory breast cancer, Breast Cancer Research and Treatment, vol.375, issue.9712, 2015.
DOI : 10.1007/s10549-015-3367-6

M. Debled, Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude, European Journal of Cancer, vol.51, issue.6, pp.697-704, 1990.
DOI : 10.1016/j.ejca.2015.01.063